Tetrindole mesylate

Discontinued Product

Tetrindole mesylate (Cat. No. 0723) has been withdrawn from sale for commercial reasons.
Cat.No. 0723 - Tetrindole mesylate | C20H26N2.CH3SO3H | CAS No. 170964-68-8
Description: MAO-A inhibitor
Chemical Name: 2,3,3a,4,5,6-Hexahydro-8-cyclohexyl-1H-pyrazino[3,2,1-j,k]carbazole mesylate
Purity: ≥99% (HPLC)
Citations (1)
Literature (4)

Biological Activity for Tetrindole mesylate

Tetrindole mesylate is a novel antidepressant, a selective inhibitor of MAO-A.

Technical Data for Tetrindole mesylate

M. Wt 390.54
Formula C20H26N2.CH3SO3H
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 170964-68-8
PubChem ID 54792409
Smiles CS(O)(=O)=O.C1CCC(CC1)C1=CC=C2N3CCNC4CCCC(=C34)C2=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for Tetrindole mesylate

References for Tetrindole mesylate

References are publications that support the biological activity of the product.

Bos et al (1995) Resolution, EPC-syntheses, absolute stereochemistry, and pharmacology of the (S)-(+)- and (R)-(-)-isomers of the MAO-A inhibitor tetrindole hydrochloride. Arch.Pharm. (Wenheim) 328 619 PMID: 7492268

Korshunov et al (2000) Hemodynamic effects of tetrindol in alert normotensive mice and rats after blockade of nitric oxide synthesis. Bull.Exp.Biol.Med. 130 777 PMID: 11177242

Medvedev et al (1994) Monoamine oxidase inhibition by novel antidepressant tetrindole. Biochem.Pharmacol. 47 303 PMID: 8304974

View Related Products by Product Action

View all Monoamine Oxidase Inhibitors

Keywords: Tetrindole mesylate, Tetrindole mesylate supplier, MAO-A, inhibitors, inhibits, Monoamine, Oxygenases, Oxidases, Oxidase, Adrenergic, Related, Compounds, Dopaminergic-Related, 5-HT-Related, 5-HT3, Receptors, 0723, Tocris Bioscience

1 Citation for Tetrindole mesylate

Citations are publications that use Tocris products. Selected citations for Tetrindole mesylate include:

Ulferts et al (2016) Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C. Antimicrob Agents Chemother 60 2627 PMID: 26856848

Reviews for Tetrindole mesylate

There are currently no reviews for this product. Be the first to review Tetrindole mesylate and earn rewards!

Have you used Tetrindole mesylate?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.


Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.


Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.